dc.contributor.author | Soydal, Çiğdem | |
dc.contributor.author | Köksoy, Elif Berna | |
dc.contributor.author | Yaşar, Hatime Arzu | |
dc.contributor.author | Turgal, Ebru | |
dc.contributor.author | Doğanay Erdoğan, Beyza | |
dc.contributor.author | Akbulut, Hakan | |
dc.contributor.author | Küçük, Nuriye Özlem | |
dc.date.accessioned | 2021-11-01T14:58:18Z | |
dc.date.available | 2021-11-01T14:58:18Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.issn | 1619-7089 | |
dc.identifier.uri | https://hdl.handle.net/11491/6577 | |
dc.description | Annual Congress of the European-Association-of-Nuclear-Medicine -- OCT 15-19, 2016 -- Barcelona, SPAIN | en_US |
dc.description.abstract | Aim: To define the role of 18F-flourodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in the detection of bone marrow (BM) involvement in patients with diffuse large B cell lymphoma (DLBCL).
Materials and methods: Fifty-four (mean age: 55.5 ± 18.3 years, 20 female and 34 male) DLBCL patients who underwent pretreatment 18F-FDG PET/CT were included to the study. Focal or diffuse BM 18F-FDG uptake that is higher than mediastinal blood pool uptake was accepted as positive. After staging of disease by CT and 18F-FDG PET/CT, all the patients received R-CHOP treatment after diagnostic blinded bone marrow biopsy (BMB). Presence of positive BM uptake in 18F-FDG PET/CT and histopathological examination results of BMBs were analyzed by Chi-square test. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of 18F-FDG PET/CT in the detection of BM involvement were calculated. Prognostic importance of the presence of BM 18F-FDG uptake was analyzed by Kaplan-Meier analysis.
Results: BM 18F-FDG uptake was detected in 8 patients. Histopathological examination of BMB revealed BM involvement in 6 out of 8 patients. BMB was negative in all patients who have no 18F-FDG uptake in the evaluation of PET/CT images. Sensitivity, specificity, accuracy, PPV, and NPV of 18F-FDG PET/CT in the detection of BM involvement were calculated as 100%, 96%, 96%, 75%, and 100%, respectively. In the Kaplan-Meier analysis, we found that presence of pretreatment 18F-FDG uptake in BM has a prognostic importance. Whereas mean time to progression (TTP) in patients with BM uptake was 32.25 ± 10.9 months and mean TTP in those without was 51.69 ± 3.6 months (p = 0.013).
Conclusions: BM uptake in pretreatment 18F-FDG PET/CT is an important prognostic factor in DLBCL patients. Moreover, in consideration of high NPV, 18F-FDG PET/CT could eliminate unnecessary BMB in FDG-negative patients. | en_US |
dc.description.sponsorship | European Assoc Nucl Med | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | European Journal Of Nuclear Medicine And Molecular Imaging | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Prognostic Importance of Bone Marrow Uptake on Baseline 18F-FDG Positron Emission Tomography/Computed Tomography in Diffuse Large B-Cell Lymphoma | en_US |
dc.type | conferenceObject | en_US |
dc.department | [Belirlenecek] | en_US |
dc.authorid | kucuk, nuriye ozlem / 0000-0002-0717-8261 | |
dc.authorid | Soydal, Cigdem / 0000-0002-6199-8551 | |
dc.identifier.volume | 43 | en_US |
dc.identifier.startpage | S317 | en_US |
dc.identifier.endpage | S318 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Soydal, C.; Kucuk, N. O.] Ankara Univ, Fac Med, Dept Nucl Med, Ankara, Turkey; [Koksoy, E.; Yasar, A.; Akbulut, H.] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey; [Turgal, E.] Hitit Univ, Fac Med, Biostat Dept, Corum, Turkey; [Erdogan, B. Doganay] Ankara Univ, Fac Med, Biostat Dept, Ankara, Turkey | en_US |
dc.contributor.institutionauthor | Turgal, Ebru | |
dc.authorwosid | kucuk, nuriye ozlem / AAG-8059-2020 | |
dc.authorwosid | Soydal, Cigdem / AAG-7968-2020 | |
dc.description.wospublicationid | WOS:000391802400191 | en_US |